Babao Dan Reverses Multiple-Drug Resistance in Gastric Cancer Cells via Triggering Apoptosis and Autophagy and Inhibiting PI3K/AKT/mTOR Signaling

Zhao, Jinyan; Lan, Weilan; Peng, Jun; Guan, Bin; Liu, Jie; Zhang, Min; Zhan, Zhixue; Lin, Jiumao

doi:https://doi.org/10.1155/2021/5631942

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Data Availability Disclosure Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2021 | Article ID 5631942 | https://doi.org/10.1155/2021/5631942

Babao Dan Reverses Multiple-Drug Resistance in Gastric Cancer Cells via Triggering Apoptosis and Autophagy and Inhibiting PI3K/AKT/mTOR Signaling

Jinyan Zhao,^1,2,3Weilan Lan,¹Jun Peng,^1,2Bin Guan,⁴Jie Liu,¹Min Zhang,¹Zhixue Zhan,⁴and Jiumao Lin^1,2,3

Academic Editor: Daniela Russo

Received25 Apr 2021

Revised11 Jun 2021

Accepted25 Jun 2021

Published09 Jul 2021

Abstract

Multidrug resistance (MDR) is a critical reason for cancer chemotherapy failure. Babaodan (BBD) is a famous traditional Chinese patent medicine reported to have antigastric cancer activity. However, the roles and molecular mechanisms of the reversal of MDR of gastric cancer by BBD have not been well described until now. Therefore, the purpose of this study was to elucidate further the role of BBD in reversing the MDR of gastric cancer cells and its specific regulatory mechanism via in vitro experiments. To verify our results, MTT, Doxorubicin (DOX) staining, Rhodamin123 (Rho123) staining, DAPI staining, Annexin V-FITC, propidium iodide (PI), Cyto-ID, and western blot assays were performed. To determine whether BBD triggers apoptosis and autophagy through the PI3K/AKT/mTOR signaling, we also applied 3-methyladenine (3-MA), chloroquine (CQ), and 740Y-P (an activator of PI3K). The results showed that BBD reversed the MDR and induced apoptosis and autophagy of SGC7901/DDP cells. Pathway analyses suggested BBD inhibits PI3K/AKT/mTOR pathway activity and subsequent apoptosis-autophagy induction. Inhibition of autophagy with 3-MA and chloroquine (CQ) was performed to confirm that BBD promoted autophagy. PI3K agonist, 740Y-P, further verified BBD inhibition of PI3K/AKT/mTOR pathway activation. In conclusion, BBD may reverse the MDR of gastric cancer cells, induce apoptosis, and promote autophagy via inactivation of the PI3K/AKT/mTOR signaling pathway.

1. Introduction

Gastric cancer (GC) is the third most common cancer worldwide and is associated with high mortality [1, 2]. Gastric cancer incidence and mortality are the highest in East Asia, especially in China [3–5]. The occurrence of stomach cancer is multifactorial, influenced by environmental bacteria, host responses, genetic and epigenetic molecular changes, Helicobacter pylori infection, among other factors [6, 7]. The current primary treatment for gastric cancer is surgical resection; however, some advanced or relapsed GC patients are not candidates for surgical treatment, so chemotherapy serves as a lead alternative therapy, especially for advanced gastric cancer [3]. Although medical advances in gastric cancer have improved, patients’ predictive and overall survival rates remain poor due to their limited and complex response to chemotherapy [5]. In addition, multidrug resistance is the leading cause of low survival time, which leads to the failure of chemotherapy for tumors and limited efficacy in most patients with gastric cancer. Therefore, how to reverse multidrug resistance remains a major clinical challenge.

Multidrug resistance (MDR) involves different mechanisms that induce cancer cells to develop cross-resistance to various structurally and mechanically unrelated chemotherapy agents, thereby limiting the long-term effective use of chemotherapy drugs [8]. One mechanism mediating MDR is through the regulation of cancer cell apoptosis and autophagy by anticancer medications [9]. Another critical mechanism involves the increased outflow of drugs from cancer cells by upregulated transport proteins that rely on specific energy sources such as ABCB1, ABCC1, and ABCG2 [10]. Other mechanisms that may contribute to drug resistance include EMT, DNA damage repair, drug target mutations, and stem cell modification [11, 12].

Babaodan (BBD) has a long medical history originating from palace secret recipes. It consists of Moschus, natural Calculus Bovis, snake gall, pearl, antelope horn, radix notoginseng, and other precious Chinese medicinal materials. Such components act through clearing away wetness-heat, promoting circulation, detoxification, and pain relief. Many clinical and experimental studies have demonstrated significant antitumor activity by BBD. In addition, these studies highlighted BBD’s promising clinical efficacy during posttumor chemotherapy and use as adjuvant therapy for various cancers, including GC [13–16]. Preliminary experimental results corresponding to clinical studies suggest that BBD could significantly inhibit gastric cancer cell proliferation and metastasis and induce their apoptosis [13, 16]. However, the specific regulatory mechanisms by which BBD reverses MDR have not been well studied. Therefore, the purpose of this study was to further elucidate the role of BBD in reversing gastric cancer cell MDR and its specific regulatory mechanism through in vitro experiments to provide an experimental basis for the clinical treatment of patients with gastric cancer drug resistance.

2. Materials and Methods

2.1. Reagents

Babaodan (Chinese FDA approval No. Z10940005) was provided by Xiamen Traditional Chinese Medicine Co., Ltd., China. Fetal bovine serum (FBS) and RPMI-1640 medium were purchased from ThermoFisher Scientific, Inc. (Waltham, MA, USA). Cisplatinum (DDP, 100 mg, MKG2946) was purchased from Millipore-Sigma (MA, USA). FITC-Annexin V/propidium iodide (PI) apoptosis assay kit (cat. no. KGA108) was purchased from Nanjing KeyGene Biotech Co., Ltd. (Nanjing, China). Antibodies to Bax (cat. no. 50599-2), Bcl-2 (cat. no. 12789-1), caspase-3 (cat. no.19677-1), LC3 (cat. no.14600-1-AP), p62 (cat no. 18420-1AP), Beclin 1 (cat. no. 11306-1-AP), PI3K (cat. no. 60225-1), AKT (cat. no. 60203-2), p-AKT (cat. no. 66444-1), and GAPDH (cat no. 60004) were purchased from Proteintech (Chicago, IL, USA). ABCB1 (cat no. 13978), ABCC1 (cat no. 72202), ABCG2 (cat. no. 42078), cleaved caspase-3 (cat. no. 9664), mammalian target of rapamycin (mTOR) (cat no. 2983), and phospho-mTOR (cat no. 5536) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The enhanced chemiluminescent (ECL) substrate for horseradish peroxidase (HRP) activity was acquired from Proteintech (Chicago, IL, USA). Other reagents, if not explicitly mentioned, were obtained from Nest (Wuxi, China).

BBD (No.180901) was purchased from Xiamen Traditional Chinese Medicine Factory Co., Ltd. (Xiamen, China). The BBD micropowder was diluted in PBS and further diluted with RPMI-1640 medium to different concentrations (0, 0.25, 0.5, and 1.0 mg/ml) prior to use.

2.2. Cell Lines and Culture

The human gastric carcinoma parental cell line SGC7901 and cells resistant to DDP (SGC7901/DDP) were obtained from the BeNa Culture Collection (Beijing Be Na Chuanglian Biotechnology Research Institute, Beijing, China). SGC7901/DDP cells were cultured in RPMI-1640 containing 10% FBS, 100 μg/mL streptomycin, 100 U/mL penicillin, and 1 μg DDP (maintaining drug resistance). The cells were incubated at 37°C in a 5% CO₂ atmosphere. For the follow-up experiments, the cells were entirely cultured in RPMI 1640 without DDP.

2.3. MTT Assays

We used an MTT assay to validate drug resistance in SGC7901/DDP cells and evaluate the effects of BBD. Briefly, cells (1 × 10⁴ cells/well) in a logarithmic growth phase were seeded in 96-well plates. The next day, we replaced the original medium with media containing different drugs: 5-FU (0–25600 μM), DOX (0–256 μM), and DDP (0–40 μM) and various concentrations of DDP combined with 0.5 mg/mL of BBD solutions with RPMI-1640 complete medium. The cell drug resistance was validated, and the reversal effect of BBD on cell viability was evaluated. After incubation with the drug for 48 h, SGC7901/DDP cells were supplemented with 100 μl culture medium containing (0.5 mg/ml) MTT and incubated for 4 h (37°C, 5% CO₂). Cells were then suspended in 100 μl DMSO. Relative cell viability (A value) was determined using a plate reader (Multiskan FC, Thermo Fisher Scientific) at an absorbance of 570 nm. We used SPSS 21.0 to calculate IC50 based on the drug resistance index (RI) = IC50 (SGC7901/DDP)/IC50 (SGC7901) and reversal fold (RF) = IC50 (DDP/DOX/5FU)/IC50 (DDP/DOX/5FU + 0.5 mg/mL BBD) was calculated.

2.4. DOX and Rho123 Staining

SGC7901/DDP cells were seeded at a density of 4.0 × 10⁵ in 6-well plates and cultured overnight. When the cells reached 50%∼60%, different concentrations of BBD (0, 0.25, 0.5, and 1.0 mg/mL) were added and incubated for 48 h. Next, the supernatant was discarded, and 1 mL PBS was added to wash the cells three times. We used 4% paraformaldehyde to fix the cells for 10 min and then washed the cells with PBS 3 times. DOX (5 μM) or Rho123 (5 μM) staining solution was added and incubated with the cells for 15 min, followed by three 1 mL PBS washes. The samples were then observed and photographed with an inverted fluorescence microscope (400x).

2.5. DAPI Staining

After cell intervention, 4% paraformaldehyde was added to fix the cells for 15 min. Next, 10% DAPI staining solution (in PBS) was added to each well and cultured in the darkness for 15 min. The cells were then washed by PBS 3 times and imaged with a fluorescence microscope (400x).

2.6. Apoptosis Assays

The apoptotic rate was determined by flow cytometry. The Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) apoptosis detection kit (Nanjing KeyGene Biotech Co., Ltd. Nanjing, China) was used. SGC-7901/DDP cells in a logarithmic growth phase were plated in six-well plates at the density of 4.0 × 10⁵ cells per well and treated with different concentrations of BBD (0, 0.25, 0.5, and 1.0 mg/mL) for 48 h, and 1 × 10⁶ cells were collected and washed twice with cold PBS. Cells were resuspended in 500 μl 1 × binding buffer and then incubated for 15 min at room temperature in the dark following 5 μl Annexin V/FITC and 5 μl PI additions. For each analysis, 10,000 events were recorded.

2.7. Cyto-ID Autophagy Detection

SGC-7901/DDP cells were treated with different concentrations of BBD for 48 h, and the cells were centrifuged. Then, the 1 × 10⁶ cells in the pellet were resuspended in 0.5 ml of freshly diluted Cyto-ID green detection reagent (1 μL Cyto-ID green detection reagent mixed with RPMI-1640 medium to a final volume of 2 mL). After incubation for 30 min at 37°C in the dark, the cells were identified by flow cytometry.

2.8. Western Blot Analysis

Protein expressions of Bax, Bcl-2, caspase-3, cleaved caspase-3, GAPDH, LC3, p62, Beclin 1, PI3K, AKT, p-AKT mTOR, and p-mTOR were examined by western blot analysis. After treated with BBD as above, SGC-7901/DDP cell proteins were extracted by radioimmunoassay (RIPA) buffer with an inhibitor cocktail (Thermo Fisher Scientific, USA) centrifuged at 14,000 rpm for 20 min at 4°C. The final supernatants were harvested, and protein concentrations were determined by a BCA protein assay kit. Total protein (30 μg) was electrophoresed on 10% SDS-PAGE and then transferred to a PVDF membrane. Following incubation with 5% skimmed milk for 1 h at room temperature, primary antibodies (1 : 1000) were diluted with TBST solution and incubated with the membranes overnight at 4°C, washed 3 times (TBST, 10 min), and then incubated with secondary antibodies (HRP-conjugated 1 : 5000) for 1 h. Finally, we used Image Lab (Bio-Rad Laboratories, Inc., Berkley, California, USA) to detect protein. Three independent experiments were performed to obtain representative data.

2.9. Statistical Analysis

All representative data were obtained from three independent experiments. Statistical analyses were performed using IBM SPSS Statistics 21 software. values <0.05 were considered to be statistically significant.

3. Results

3.1. SGC7901/DDP Cell Line Exhibited Multidrug-Resistant Cells

We utilized the resistance index (RI) to evaluate the resistance of MDR cells to various anticancer drugs. The SGC-7901/DDP cells exhibit MDR (RIs > 1.5) to DDP, DOX, and 5-fluorouracil (5-FU) with a corresponding RI of 1.86, 1.501, and 47.70, respectively (Table 1).

3.2. BBD Reversed the MDR of the SGC-7901/DDP

The ability of BBD to reverse the resistance of SGC-7901/DDP cells to several chemotherapeutic drugs is shown in Table 2. The reversal effect was evaluated by reversal fold (RF), with an RF > 1.5 indicating enhanced drug sensitivity. BBD (0.5 mg/mL) improved the sensitivity of SGC-7901/DDP cells to DDP, DOX, and 5-FU by 1.55-fold, 4.68-fold, and 3.56-fold, respectively. The results indicated that BBD significantly increased the cytotoxicity of anticancer drugs in SGC7901/DDP cells (Table 2).

3.3. BBD Downregulated ABCB1, ABCC1, and ABCG2 Expression and Increased the Accumulation of DOX and Rho123 in Gastric Cancer-Resistant Cells

The accumulation and efflux of chemotherapeutic drugs from tumor cells into the surrounding tissue in cells are important indicators for assessing MDR reversal. Our findings showed that 0.25, 0.5 and 1.0 mg/mL BBD increased the accumulation values of DOX to 6.03 ± 0.28, 7.13 ± 1.03, and 12.55 ± 1.15, over the levels in control cells (3.86 ± 0.19), respectively () (Figures 1(a) and 1(b)), and the accumulation values of Rho123 were 5.4 ± 0.12, 14.7 ± 1.21, and 21.5 ± 1.78, over control cells (2.1 ± 0.15), respectively () (Figures 1(c) and 1(d)). ABC family protein accounts for the accumulation of drugs. Western blot results showed that treatment with BBD (0.25, 0.5, or 1.0 mg/mL) significantly reduced the expressions of ABCB1, ABCC1, and ABCG2 compared with the control group (). ABCB1 expression rates were (100.00 ± 1.86)%, (65.35 ± 1.27)%, (56.86 ± 2.42)%, and (44.83 ± 2.19)% (); ABCC1 expression rates were (100.00 ± 4.19)%, (90.16 ± 2.93)%, (84.38 ± 1.52)%, and (67.25 ± 3.73)% (); ABCG2 expression rates (100.00 ± 6.46)%, (76.35 ± 5.63)%, (38.44 ± 5.76)%, and (19.36 ± 4.65)% (), respectively (Figures 1(e) and 1(f)).

(a)

(b)

(c)

(d)

(e)

(f)

Figure 1

BBD increased doxorubicin and Rho123 accumulation and downregulated the protein expression of ABCB1, ABCC1, and ABCG2 in gastric cancer-resistant cells. SGC7901/DDP cells were treated with BBD (0.25, 0.5, or 1.0 mg/mL) for 48 h, doxorubicin and Rho123 staining were observed via fluorescence microscope ((a) and (c)), and the average fluorescence intensity of all the cells was calculated in five random fields ((b) and (d)). Expression and quantitative analyses of ABCB1, ABCC1, and ABCG2 protein are shown ((e) and (f)). and .

3.4. BBD Induced Apoptosis of SGC7901/DDP Cells

Resistance to apoptosis is one of the most important factors that contribute to MDR. As such, apoptotic induction may be a strategy to overcome MDR. The proapoptotic activity of BBD in SGC7901/DDP cells was tested by assessing DAPI and Annexin V/PI staining. DAPI staining showed that BBD could induce punctate apoptotic body formation, as shown in Figures 2(a) and 2(b). In cells treated with varying concentrations of BBD (0, 0.25, 0.5, and 1.0 mg/mL), Annexin V/PI staining was assessed via flow cytometry. The findings showed that the percentage of apoptotic cells was (4.54 ± 0.24)%, (7.54 ± 0.84)%, (14.49 ± 0.39)%, and (14.64 ± 1.36)%, respectively. Apoptosis was significantly elevated (), as shown in Figures 2(c) and 2(d). We also found that BBD regulated the expression of apoptosis-related proteins (Figure 2(e)). The expression levels of the Bcl-2 expression rate were (100 ± 1.34)%, (83.70 ± 1.33)%, (70.76 ± 0.76)%, and (49.56 ± 0.12)%, respectively (); the expression rates of Bax were (100 ± 1.21)%, (131 ± 1.17)%, (164.33 ± 1.05)%, and (156.53 ± 1.30)%, respectively (); the expression rates of cleaved caspase-3 were (100 ± 4.41)%, (116.82 ± 4.73)%, (121.63 ± 3.64)%, and (131.66 ± 2.65)%, respectively (); the expression rates of caspase-3 were (100 ± 3.12)%, (100.32 ± 3.69)%, (91.53 ± 1.96)%, and (98.04 ± 2.82)% respectively () (Figure 2(f)). The above results suggest that BBD overcomes MDR in SGC-7901/DDP cells via apoptotic induction.

(a)

(b)

(c)

(d)

(e)

(f)

Figure 2

BBD induces apoptosis of SGC7901/DDP cells. SGC7901/DDP cells were treated with BBD (0.25, 0.5, and 1.0 mg/mL) for 48 h, and fluorescence microscopy was used to observe DAPI nuclear staining (a), and the average fluorescence intensity of all nuclei was calculated in five random fields (b). Annexin V/PI staining was used in flow cytometry to assess the proapoptotic effects of BBD (c). Data from apoptotic cell quantification (d). Cleaved caspase-3, caspase-3, Bcl-2, and Bax expression levels were detected by western blot (e). The quantification of each protein is shown (f). , versus controls.

3.5. BBD Promoted Autophagy in SGC-7901/DDP Cells

To explore whether autophagy contributed to cell death, we assessed BBD treatment effects on autophagy in SGC-7901/DDP cells. Fluorescence microscope observation showed that the formation of green autophagy vacuoles and the fluorescence intensity were (1.0 ± 0.99)%, (6.5 ± 0.127)%, (10.4 ± 1.31)%, and (21.60 ± 1.92)% (), as shown in Figures 3(a) and 3(b). Flow cytometry was further used to detect the fluorescence intensity of gastric cancer drug-resistant cells after Cyto-ID staining, and the fluorescence intensity values were (21.63 ± 1.28)%, (30.31 ± 1.66)%, (32.47 ± 0.75)%, and (35.58 ± 0.84)% () (Figures 3(c) and 3(d)). The Cyto-ID staining results showed that BBD promoted autophagy in SGC-7901/DDP cells. Moreover, we assessed autophagy-related protein expression and found that BBD increases the protein levels of LC3-II and Beclin 1 but decreased the expression of p62 compared with control cells (Figures 3(e) and 3(f)). Meanwhile, we used 3-MA and CQ to further confirm the role of autophagy in SGC-7901/DDP cells. 3-MA (an early inhibitor of autophagy) of 10 mM blocked the expression of LC3-II (Figures 4(a) and 4(b)), while CQ (a late inhibitor of autophagy) of 5 μM upregulated the expression of LC3-II and p62. BBD upregulated LC3II, downregulated p62 expression, and promoted autophagy in drug-resistant gastric cancer cells (Figures 4(c) and 4(d)). Based on these results, we concluded that BBD promotes SGC-7901/DDP cell autophagy.

(a)

(b)

(c)

(d)

(e)

(f)

(a)

(b)

(c)

(d)

3.6. BBD Promoted Autophagy-Induced Apoptosis in SGC-7901/DDP Cells by Inhibiting the PI3K/AKT/mTOR Pathway

Abnormal activation of PI3K/AKT/mTOR signaling is an important mechanism for promoting cancer biology. We examined whether BBD affects the PI3K/AKT/mTOR signaling pathway as a mechanism for its effects on the MDR of GC. Our results showed that BBD reduced p-PI3K, p-AKT, and p-mTOR expression and inhibited the PI3K/AKT/mTOR signaling (Figure 5). In addition, PI3K/AKT/mTOR is a common signaling pathway that regulates autophagy and apoptosis. To determine whether BBD regulated autophagy-induced apoptosis through the PI3K/AKT/mTOR signaling, we applied 740Y-P (an activator of PI3K) to the cells. As expected, 740Y-P inhibited autophagy and apoptosis. These results confirmed that BBD reversed MDR of GC via PI3K/AKT/mTOR signaling (Figures 6(a) and 6(b)). In addition, after 740Y-P and BBD intervention, apoptosis and autophagy-related protein results showed that 740Y-P inhibited apoptosis and autophagy in SGC7901/DDP cells, while BBD promoted apoptosis and autophagy in SGC7901/DDP cells (Figures 7(a) and 7(b)).

(a)

(b)

(a)

(b)

(a)

(b)

4. Discussion

With recent rapid developments in the Chinese economy, continuous improvement of people’s living standards, and changes in the environment and diet, the incidence of gastric cancer has increased annually, which is a severe threat to human health. As a result, gastric cancer has become an undeniable social health problem. Over decades of medical research and therapeutic development, several chemotherapeutic regimens based on different anticancer drugs have improved the survival of many GC patients. However, chemotherapy in GC patients often fails due to the cancer cells’ development of multidrug resistance (MDR) [17]. Therefore, increased emphasis has recently been placed on screening high efficiency and low toxicity drugs that can reverse or diminish tumor resistance. In the present study, we demonstrate that BBD may reverse MDR by downregulating PI3K/AKT/mTOR signaling to induce autophagy and apoptosis in the human drug-resistant cell line SGC-7901/DDP.

BBD, a traditional Chinese medicine formula, has the characteristics of a multicomponent, multitarget therapy and is widely used in cancer treatment. Preliminary studies have reported that BBD has been widely used to treat patients with various cancers with noted prevention of complications [13–16]. Wang et al. found that BBD can inhibit cell growth by inducing autophagy through PI3K/AKT/mTOR signaling and enhancing the antitumor effect of cisplatin in non-small-cell lung cancer (NSCLC) cells [18]. Still, the regulatory mechanism of BBD in GC multidrug resistance has not been fully clarified. Therefore, in this study, we first detected the drug resistance of gastric cancer drug-resistant cell lines. It was found that SGC7901/DDP drug-resistant cell lines had multidrug resistance, and the drug resistance index was RIs > 1.5. To verify the effect of BBD on the multidrug resistance of gastric cancer, we used low concentrations of BBD (0.25, 0.5 mg/mL) combined with different concentrations of chemotherapy drugs (DDP, DOX, and 5-FU) to treat gastric cancer drug-resistant cells. Compared with DDP, DOX, and 5-FU alone, our results showed that the RF values of 0.25 and 0.5 mg/mL BBD on DDP, DOX, and 5-FU were greater than 1.5, indicating that BBD reversed the drug resistance of gastric cancer drug-resistant cells. To further clarify the mechanism of its reversal of drug resistance, we analyzed cell drug resistance, apoptosis, autophagy, and the regulation mechanism of SGC7901/DDP.

It is well known that ABC transport protein-mediated MDR is one of the crucial causes of tumor chemotherapy failure [19, 20]. Therefore, potential molecular targets or biomarkers must be sought to mitigate MDR. P-gp (MDR1/ABCB1) relies on ATP energy to pump hydrophobic drugs from cells, which reduces intracellular drug concentration and causes resistance in tumor cells [21]. The expression of ABCB1 protein has been shown to be elevated in chemotherapy-resistant gastric cancer tissue compared to chemotherapy-sensitive cancer [22]. MRP (ABCC1) can transfer a combination of GSH and related drugs out of cells, leading to drug resistance [23]. Chen et al. found that ABCC1 increased the protein and gene expression of ABCC1 in a cancer cell line and induced in vitro gastric cancer cell line (SGC-7901/AS) resistant to arsenic trioxide [23–25]. ABCG2 is involved in mediating MDR by reducing drug penetration and intestinal absorption [26]. Accordingly, inhibiting ABCG2 can reduce MDR phenotypes and improve chemotherapy outcomes. Recent literature demonstrates that MDR1, MRP, and P-gp protein levels in SGC-7901/DDP and SGC-7901/VCR cells are increased [27]. Therefore, MDR1, ABCC1, and ABCG2 expressions were first measured in SGC-7901/DDP cells. Our findings indicate that BBD treatment for 48 h significantly lowers ABCB1, ABCC1, and ABCG2 expressions in SGC-7901/DDP cells, consistent with previous reports.

Apoptosis is an important defense mechanism to eliminate malignant cells and prevent cancer progression. The primary function of many antitumor drugs is to induce tumor apoptosis through various apoptosis-related signaling pathways [28]. One of the important mechanisms for the development of MDR in cancer cells in response to chemotherapy is to inhibit or evade apoptosis [29, 30]. There are two primary pathways tumor cells are stimulated to undergo apoptosis, the death receptor pathway (exogenous), and the mitochondrial-dependent pathway (endogenous). The key regulatory factors of endogenous pathways are Bcl-2 family proteins, including antiapoptotic factor Bcl-2 and proapoptotic factor Bax [31]. Overexpression of Bcl-2 and underexpression of Bax reduce cancer cell sensitivity to chemotherapy drugs to avoid apoptosis. Liquiritin (LIQ) has been shown to inhibit drug-induced apoptosis by increasing Bax and reducing Bcl-2 in cisplatin (DDP)-resistant gastric cancer cells [32]. Of the caspases, caspase-3 is the one most associated with several apoptotic pathways [33]. Therefore, BBD has been shown to overcome drug resistance and induce apoptosis in SGC7901/DDP cells by increasing Bax and cleaved caspase-3 expression while reducing Bcl-2 expression.

Autophagy is another molecular mechanism that induces cell death. Consequently, autophagy plays a vital role in preventing tumor growth in drug discovery [34, 35]. Extensive evidence suggests that increasing autophagy may help reverse MDR [36, 37]. For example, Wei et al. found that LIQ can induce apoptosis and autophagy by arresting the cell cycle at G0/G1 phase and enhancing the proapoptotic effect of DDP on human gastric cancer SGC7901/DDP cells [32]. Kou et al. found that Berberine improves chemosensitivity to cisplatin by enhancing apoptosis and repressing PI3K/AKT/mTOR signaling in gastric cancer [38]. Recent studies have confirmed autophagy as a scavenger in the apoptosis-blocked signal pathway, making MDR tumors sensitive to apoptosis [39]. As shown in Figure 3(a), fluorescence labeling showed that BBD treatment severely disrupted cell morphology. Western blot analysis demonstrated that BBD treatment greatly induced autophagy-related signals of LC3II and Beclin 1 but suppressed p62, leading to autophagy in SGC7901/DDP cells (Figures 3(e) and 3(f))

To verify the effect of BBD on the early autophagy of gastric cancer drug-resistant cells, BBD and 3-MA (an early autophagy inhibitor) were used to treat SGC7901/DDP cells. The results showed that 3-MA downregulated the expression of LC3II and inhibited early autophagy in SGC7901/DDP cells. BBD upregulated LC3II expression and promoted early autophagy in SGC7901/DDP cells. With 3-MA and BBD combined, the expression of LC3II was not completely blocked by 3-MA, suggesting that BBD may promote early autophagy in SGC7901/DDP cells through other mechanisms. For example, Bcl-2 inhibits Beclin 1-dependent autophagy or mitochondrial autophagy. In order to verify the effect of BBD on the advanced autophagy of gastric cancer drug-resistant cells, CQ (a late autophagy inhibitor) and BBD were used to intervene in SGC7901/DDP cells. The experimental results showed the with CQ and BBD intervention, CQ promoted the expression of LC3II and p62, and p62 inhibited advanced autophagy in SGC7901/DDP cells. Meanwhile, BBD downregulated p62 and promoted advanced autophagy. After a combined treatment of CQ with BBD, there was no significant difference in the expression of p62 compared with the CQ group, indicating that advanced autophagy induced by BBD was blocked by CQ.

Activation of the PI3K/AKT/mTOR signaling pathway has been shown to have carcinogenic effects in gastric cancer, and its regulatory pathways are closely related to genetic variation, cell proliferation, migration, invasion, cell cycle, apoptosis, autophagy, angiogenesis, multidrug resistance, and cell viability [21, 40–47]. Guo et al. found that Ubenimex inhibited the phosphorylation and activation of the PI3K/AKT/mTOR pathway and downregulated membrane transporter (such as P-gp and MRP1) expression, resulting in the intracellular accumulation of 5-fluorouracil and oxaliplatin [48]. Chen et al. reported that proton pump inhibitors inhibited the V-ATPase/PI3K/AKT/mTOR/HIF-1 alpha signaling pathways and downregulated TSC1/2 and Rheb expression in gastric cancer cells to reverse multidrug resistance [49]. In addition, Wang et al. found Babaodan induced autophagy and inhibited cell growth through the PI3K/AKT/mTOR pathway and enhanced antitumor effects of cisplatin in NSCLC cells [18]. So, the PI3K/AKT/mTOR signaling pathway was investigated to further elucidate the mechanism of BBD in reversing the MDR of the gastric cancer cell. Surprisingly, we found that several phosphorylated products in this pathway, such as p-PI3K, p-AKT, and p-mTOR, were reduced by BBD (Figure 5).

To further verify the inhibitory effect of BBD on this pathway, we used the PI3K agonist (740Y-P). As shown in Figures 6(a) and 6(b), our results showed that 740Y-P could significantly upregulate the phosphorylation of PI3K/AKT/mTOR proteins in SGC7901/DDP cells and promote the activation of this pathway, while BBD inhibited PI3K/AKT/mTOR signaling. When 740Y-P was combined with BBD, the inhibitory effect of BBD on this signaling pathway was offset by 740Y-P. The results of the 740Y-P intervention were consistent with prior reports [50], which showed that BBD could inhibit PI3K/AKT/mTOR signaling pathway activation and reverse MDR of SGC7901/DDP cells.

In addition, we further explored the role of the PI3K/AKT/mTOR pathway in BBD modulation of apoptosis and autophagy. As shown in Figures 7(a) and 7(b), our results indicate that 740Y-P-mediated activation of PI3K had a catalytic effect on p-PI3K, p-AKT, and p-mTOR and increased Bcl-2 and p62 expressions. In addition, it reduced Bax, autophagy-associated LC3II/I ratio, and Beclin 1 expression and inhibited apoptosis and autophagy in SGC7901/DDP cells. BBD downregulated Bcl-2 and p62 expression and promoted the expression of Bax, LC3II, and Beclin 1, promoting apoptosis and autophagy in SGC7901/DDP cells. After a therapy of BBD combined with 740Y-P, BBD promoted the apoptosis and autophagy of SGC7901/DDP cells, which were weakened or canceled by 740Y-P. These results showed that BBD can reverse MDR in gastric cancer cells via inactivating PI3K/AKT/mTOR signaling to induce apoptosis and autophagy.

5. Conclusions

In conclusion, the results of the present study indicate that BBD may be a promising candidate for the treatment of MDR in gastric cancer. However, as our study was performed only in vitro, additional studies are needed in animal models or humans to further confirm these therapeutic effects of BBD in gastric cancer.

Data Availability

The original data used to support the findings of this study are available from the corresponding author upon request.

Disclosure

This manuscript has been submitted as a preprint in Research Square. Jinyan Zhao and Weilan Lan are joint authors.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Authors’ Contributions

Jinyan Zhao and Weilan Lan contributed equally to this work. Jiumao Lin, Jun Peng, and Jinyan Zhao designed the experiments. Weilan Lan, Bin Guan, Jie Liu, Min Zhang, and Zhixue Zhan carried out the supplement preparation and laboratory experiments. Jiumao Lin and Jinyan Zhao analyzed the data and interpreted the results. Weilan Lan prepared figures and wrote the manuscript.

Acknowledgments

This work was supported by Xiamen Traditional Chinese Medicine Co., Ltd.

References

R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics,” CA: A Cancer Journal for Clinicians, vol. 69, no. 1, pp. 7–34, 2019.
View at: Publisher Site | Google Scholar
C. Chen, X. Tang, Y. Liu, J. Zhu, and J. Liu, “Induction/reversal of drug resistance in gastric cancer by non-coding RNAs,” International Journal of Oncology, vol. 54, no. 5, pp. 1511–1524, 2019.
View at: Publisher Site | Google Scholar
H. W. Pan, S. C. Li, and K. W. Tsai, “MicroRNA dysregulation in gastric cancer,” Current Pharmaceutical Design, vol. 19, pp. 1273–1284, 2013.
View at: Google Scholar
P. Zheng, L. Chen, X. Yuan et al., “Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells,” Journal of Experimental & Clinical Cancer Research, vol. 36, no. 1, p. 53, 2017.
View at: Publisher Site | Google Scholar
X. Zhou, X. Men, R. Zhao et al., “miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer,” Cancer Gene Therapy, vol. 25, no. 3-4, pp. 68–76, 2018.
View at: Publisher Site | Google Scholar
L. Li, X. Zhu, T. Shou et al., “MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway,” Molecular Medicine Reports, vol. 17, no. 3, pp. 4003–4010, 2018.
View at: Publisher Site | Google Scholar
D. C. Lazăr, S. Tăban, M. Cornianu, A. Faur, and A. Goldiş, “New advances in targeted gastric cancer treatment,” World Journal of Gastroenterology, vol. 22, no. 30, pp. 6776–6799, 2016.
View at: Publisher Site | Google Scholar
F. Corrà, C. Agnoletto, L. Minotti, F. Baldassari, and S. Volinia, “The network of non-coding RNAs in cancer drug resistance,” Frontiers in Oncology, vol. 8, p. 327, 2018.
View at: Publisher Site | Google Scholar
C. Matuszcak, J. Haier, R. Hummel, and K. Lindner, “MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential,” World Journal of Gastroenterology, vol. 20, no. 38, pp. 13658–13666, 2014.
View at: Publisher Site | Google Scholar
W.-J. Shi and J.-B. Gao, “Molecular mechanisms of chemoresistance in gastric cancer,” World Journal of Gastrointestinal Oncology, vol. 8, no. 9, pp. 673–681, 2016.
View at: Publisher Site | Google Scholar
P. Ramos and M. Bentires-Alj, “Mechanism-based cancer therapy: resistance to therapy, therapy for resistance,” Oncogene, vol. 34, no. 28, pp. 3617–3626, 2015.
View at: Publisher Site | Google Scholar
M. Saxena, M. A. Stephens, H. Pathak, and A. Rangarajan, “Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters,” Cell Death & Disease, vol. 2, no. 7, p. e179, 2011.
View at: Publisher Site | Google Scholar
B. Huang, Z. Cao, L. Wei, J. Zhao, J. Peng, and J. Lin, “Babao dan, a traditional Chinese medicine formula, arrests the G1/S phase transition in gastric cancer cells by activating p53 pathway,” International Journal of Gerontology, vol. 14, pp. 77-78, 2020.
View at: Google Scholar
Y. L. H. Chen, “Effect on sensitivity to cisplatin after Babaodan treatment of human lung adenocarcinoma cells A549 and SPCA-1,” Journal of Binzhou Medical University, vol. 39, pp. 414–417, 2016.
View at: Google Scholar
L. J. Zhou, “Proliferation inhibition and apoptosisi induction of Ba-Bao-Dan (BBD) in human osteosarcoma U-2OS cells,” Chinese Journal of Traditional Medical Traumatology & Orthopedics, vol. S2, pp. 93–95, 2006.
View at: Google Scholar
H. Shang, Z. Cao, J. Zhao et al., “Babao Dan induces gastric cancer cell apoptosis via regulating MAPK and NF-κB signaling pathways,” Journal of International Medical Research, vol. 47, no. 10, pp. 5106–5119, 2019.
View at: Publisher Site | Google Scholar
G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, “Targeting multidrug resistance in cancer,” Nature Reviews Drug Discovery, vol. 5, no. 3, pp. 219–234, 2006.
View at: Publisher Site | Google Scholar
Q. Wang, Z. Liu, K. Du et al., “Babaodan inhibits cell growth by inducing autophagy through the PI3K/AKT/mTOR pathway and enhances antitumor effects of cisplatin in NSCLC cells,” American Journal of Translational Research, vol. 11, no. 8, pp. 5272–5283, 2019.
View at: Google Scholar
Z. Chen, T. Shi, L. Zhang et al., “Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade,” Cancer Letters, vol. 370, no. 1, pp. 153–164, 2016.
View at: Publisher Site | Google Scholar
W. Li, H. Zhang, Y. G. Assaraf et al., “Overcoming ABC transporter-mediated multidrug resistance: molecular mechanisms and novel therapeutic drug strategies,” Drug Resistance Updates, vol. 27, pp. 14–29, 2016.
View at: Publisher Site | Google Scholar
S. Basha Syed and M. Selvaraj Coumar, “P-glycoprotein mediated multidrug resistance reversal by phytochemicals: a review of SAR & future perspective for drug design,” Current Topics in Medicinal Chemistry, vol. 16, no. 22, pp. 2484–2508, 2016.
View at: Publisher Site | Google Scholar
C. Calatozzolo, M. Gelati, E. Ciusani et al., “Expression of drug resistance proteins pgp, MRP1, MRP3, MRP5 and GST-π in human glioma,” Journal of Neuro-Oncology, vol. 74, no. 2, pp. 113–121, 2005.
View at: Publisher Site | Google Scholar
D. Cao, S. Qin, Y. Mu, and M. Zhong, “The role of MRP1 in the multidrug resistance of colorectal cancer,” Oncology Letters, vol. 13, no. 4, pp. 2471–2476, 2017.
View at: Publisher Site | Google Scholar
J. Ding, X.-T. Zhou, H.-Y. Zou, and J. Wu, “Hedgehog signaling pathway affects the sensitivity of hepatoma cells to drug therapy through the ABCC1 transporter,” Laboratory Investigation, vol. 97, no. 7, pp. 819–832, 2017.
View at: Publisher Site | Google Scholar
X. Chen, M. Zhang, and L. X. Liu, “The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells,” Oncology Reports, vol. 22, no. 1, pp. 73–80, 2009.
View at: Google Scholar
M. H. Hasanabady and F. Kalalinia, “ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer,” Journal of Biosciences, vol. 41, no. 2, pp. 313–324, 2016.
View at: Publisher Site | Google Scholar
H. Zhang, H. Jiang, H. Zhang, J. Liu, X. Hu, and L. Chen, “Ribophorin II potentiates P-glycoprotein- and ABCG2-mediated multidrug resistance via activating ERK pathway in gastric cancer,” International Journal of Biological Macromolecules, vol. 128, pp. 574–582, 2019.
View at: Publisher Site | Google Scholar
X. Jin and Y. Shi, “Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways,” Experimental and Therapeutic Medicine, vol. 11, no. 2, pp. 403–408, 2016.
View at: Publisher Site | Google Scholar
S. Vega, A. V. Morales, O. H. Ocaña et al., “Snail blocks the cell cycle and confers resistance to cell death,” Genes & Development, vol. 18, no. 10, pp. 1131–1143, 2004.
View at: Publisher Site | Google Scholar
S. Terry, P. Savagner, S. Ortiz-Cuaran et al., “New insights into the role of EMT in tumor immune escape,” Molecular Oncology, vol. 11, no. 7, pp. 824–846, 2017.
View at: Publisher Site | Google Scholar
W. A. Siddiqui, A. Ahad, and H. Ahsan, “The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update,” Archives of Toxicology, vol. 89, no. 3, pp. 289–317, 2015.
View at: Publisher Site | Google Scholar
F. Wei, X. Jiang, H.-Y. Gao, and S.-H. Gao, “Liquiritin induces apoptosis and autophagy in cisplatin (DDP)-resistant gastric cancer cells in vitro and xenograft nude mice in vivo,” International Journal of Oncology, vol. 51, no. 5, pp. 1383–1394, 2017.
View at: Publisher Site | Google Scholar
A. G. Porter and R. U. Jänicke, “Emerging roles of caspase-3 in apoptosis,” Cell Death & Differentiation, vol. 6, no. 2, pp. 99–104, 1999.
View at: Publisher Site | Google Scholar
Z. J. Yang, C. E. Chee, S. Huang, and F. Sinicrope, “Autophagy modulation for cancer therapy,” Cancer Biology & Therapy, vol. 11, no. 2, pp. 169–176, 2011.
View at: Publisher Site | Google Scholar
B. Zhai, F. Hu, X. Jiang et al., “Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma,” Molecular Cancer Therapeutics, vol. 13, no. 6, pp. 1589–1598, 2014.
View at: Publisher Site | Google Scholar
P. Kumar, D.-M. Zhang, K. Degenhardt, and Z.-S. Chen, “Autophagy and transporter-based multi-drug resistance,” Cells, vol. 1, no. 3, pp. 558–575, 2012.
View at: Publisher Site | Google Scholar
J. M. M. Levy, C. G. Towers, and A. Thorburn, “Targeting autophagy in cancer,” Nature Reviews Cancer, vol. 17, no. 9, pp. 528–542, 2017.
View at: Publisher Site | Google Scholar
Y. Kou, B. Tong, W. Wu, X. Liao, and M. Zhao, “Berberine improves chemo-sensitivity to cisplatin by enhancing cell apoptosis and repressing PI3K/AKT/mTOR signaling pathway in gastric cancer,” Frontiers in Pharmacology, vol. 11, Article ID 616251, 2020.
View at: Publisher Site | Google Scholar
Y.-J. Li, Y.-H. Lei, N. Yao et al., “Autophagy and multidrug resistance in cancer,” Chinese Journal of Cancer, vol. 36, no. 1, p. 52, 2017.
View at: Publisher Site | Google Scholar
Y. J. Wu, S. H. Lin, Z. H. Din et al., “Sinulariolide inhibits gastric cancer cell migration and invasion through downregulation of the EMT process and suppression of FAK/PI3K/AKT/mTOR and MAPKs signaling pathways,” Marine Drugs, vol. 17, 2019.
View at: Publisher Site | Google Scholar
Y. Qian, Y. Yan, H. Lu et al., “Celastrus orbiculatus extracts inhibit the metastasis through attenuating PI3K/Akt/mTOR signaling pathway in human gastric cancer,” Anti-Cancer Agents in Medicinal Chemistry, vol. 19, no. 14, pp. 1754–1761, 2019.
View at: Publisher Site | Google Scholar
Y. Ge, H. Liu, X. Qiu et al., “Genetic variants in PI3K/Akt/mTOR pathway genes contribute to gastric cancer risk,” Gene, vol. 670, pp. 130–135, 2018.
View at: Publisher Site | Google Scholar
J. U. Am, W. J. Gong, Y. Su et al., “Imperatorin shows selective anti-tumor effects in SGC-7901 human gastric adenocarcinoma cells by inducing apoptosis, cell cycle arrest and targeting PI3K/Akt/m-TOR signalling pathway,” Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology, vol. 22, pp. 1471–1476, 2017.
View at: Google Scholar
O. Tapia, I. Riquelme, P. Leal et al., “The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance,” Virchows Archiv, vol. 465, no. 1, pp. 25–33, 2014.
View at: Publisher Site | Google Scholar
X. R. Zhang, S. Y. Wang, W. Sun, and C. Wei, “Isoliquiritigenin inhibits proliferation and metastasis of MKN28 gastric cancer cells by suppressing the PI3K/AKT/mTOR signaling pathway,” Molecular Medicine Reports, vol. 18, no. 3, pp. 3429–3436, 2018.
View at: Publisher Site | Google Scholar
X. Wang, X. Jiao, Y. Meng et al., “Methionine enkephalin (MENK) inhibits human gastric cancer through regulating tumor associated macrophages (TAMs) and PI3K/AKT/mTOR signaling pathway inside cancer cells,” International Immunopharmacology, vol. 65, pp. 312–322, 2018.
View at: Publisher Site | Google Scholar
H. J. Lee, V. Venkatarame Gowda Saralamma, S. M. Kim et al., “Pectolinarigenin induced cell cycle arrest, autophagy, and apoptosis in gastric cancer cell via PI3K/AKT/mTOR signaling pathway,” Nutrients, vol. 10, no. 8, 2018.
View at: Publisher Site | Google Scholar
Q. Guo, F. J. Jing, H. J. Qu et al., “Ubenimex reverses MDR in gastric cancer cells by activating caspase-3-mediated apoptosis and suppressing the expression of membrane transport proteins,” BioMed Research International, vol. 2019, Article ID 4390839, 14 pages, 2019.
View at: Publisher Site | Google Scholar
M. Chen, J. Lu, W. Wei et al., “Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo,” OncoTargets and Therapy, vol. 11, pp. 6705–6722, 2018.
View at: Publisher Site | Google Scholar
E. Xu, X. Xia, C. Jiang et al., “GPER1 silencing suppresses the proliferation, migration, and invasion of gastric cancer cells by inhibiting PI3K/AKT-Mediated EMT,” Frontiers in Cell and Developmental Biology, vol. 8, Article ID 591239, 2020.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2021 Jinyan Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

448

Downloads

762

Citations